A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

Huajun Chen(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Shundong Cang(Henan University), Shubin Tang(Neijiang Normal University), Gaowa Jin(Inner Mongolia People's Hospital), Hai‐Yan Tu(Jiangnan University), Yanping Hu(Chinese People's Liberation Army), Nong Yang(Central South University), Ximing Xu(Shanghai Changzheng Hospital), Guowu Wu(Meizhou City People's Hospital), Qing Zhou, Yun Fan(Zhejiang Cancer Hospital), Rui Ma(Liaoning Cancer Hospital & Institute), Yi Yang(Third People's Hospital of Chengdu), Anwen Liu(Nanchang University), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Yan Yu(Harbin Medical University), Ying Cheng(Jilin Province Tumor Hospital)
Research Square
November 15, 2024
10.21203/rs.3.rs-5322089/v1
Cited by 0

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k